Medical economics

Profits jab higher at insulin maker Novo Nordisk

Novo Nordisk said Friday that its new treatment for adults who suffer from diabetes drove sales and profits higher, but the world's top manufacturer of insulin still faced difficulties in the key US market.

Other

Drugmaker Novo Nordisk profits jump in diabetes scourge

Danish drugmaker Novo Nordisk, the world's leading insulin provider, on Wednesday reported a six percent jump in net profit in the first quarter, as the global onslaught of diabetes continued to grow.

Other

Novartis to buy back $5 bn in shares

Swiss pharmaceutical giant Novartis announced Wednesday a $5.0 billion share buyback even though competition from generics ate away at sales and earnings last year.

Other

GSK sees earnings rise amid good demand for vaccines

Pharmaceutical company GlaxoSmithKline says its net profit rose 50 percent in the third quarter to 808 million pounds ($986 million) thanks in part to strong sales of its vaccine products.

page 2 from 5